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R E S E A R C H

A R T I C L E

Bromodomain and Extraterminal Inhibition by JQ1
Produces Divergent Transcriptional Regulation of
Suppressors of Cytokine Signaling Genes in Adipocytes

1

Adipocyte Biology Laboratory, Pennington Biomedical Research Center, Baton Rouge, Louisiana 70808;
and 2Department of Biological Sciences, Louisiana State University, Baton Rouge, Louisiana 70803

ORCiD numbers: 0000-0002-9559-4061 (A. J. Richard).
The Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway
has cell-specific functions. Suppressors of cytokine signaling (SOCS) proteins are negativefeedback regulators of JAK-STAT signaling. STAT5 plays a significant role in adipocyte
development and function, and bromodomain and extraterminal (BET) proteins may be involved
in STAT5 transcriptional activity. We treated 3T3-L1 adipocytes with the BET inhibitor JQ1 and
observed that growth hormone (GH)-induced expression of 2 STAT5 target genes from the SOCS
family, Socs3 and Cish, were inversely regulated (increased and decreased, respectively) by BET
inhibition. Chromatin immunoprecipitation analyses revealed that changes in STAT5 binding did
not correlate with gene expression changes. GH promoted the recruitment of the BET protein
BRD2 to the Cish, but not Socs3, promoter. JQ1 treatment ablated this effect as well as the GHinduced binding of ribonucleic acid polymerase II (RNA Pol II) to the Cish transcription start site.
BRD2 knockdown also suppressed GH induction of Cish, further supporting the role of BRD2
in Cish transcriptional activation. In contrast, JQ1 increased the binding of activated Pol II to
the Socs3 coding region, suggesting enhanced messenger RNA (mRNA) elongation. Our finding
that JQ1 transiently reduced the interaction between the positive transcription elongation factor
(P-TEFb) and its inhibitor hexamethylene bis-acetamide inducible 1 (HEXIM1) is consistent with
a previously described off-target effect of JQ1, whereby P-TEFb becomes more available to be
recruited by genes that do not depend on BET proteins for activating transcription. These results
demonstrate substantially different transcriptional regulation of Socs3 and Cish and suggest
distinct roles in adipocytes for these 2 closely related proteins. (Endocrinology 161: 1–15, 2020)
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S

ignal transducers and activators of transcription
(STATs) are a family of transcription factors expressed in most cells and tissues. In mammals, there
are 7 members in the family (STATs 1, 2, 3, 4, 5A, 5B,
and 6), which are activated by different ligands, depending on cell type. Upon external stimulation, STATs
dimerize in the cytosol and translocate to the nucleus
where they control the expression of target genes (1).
The suppressors of cytokine signaling (SOCS) family
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has 8 members, SOCS1 through SOCS7 and cytokineinducible SH2-containing protein (CISH), all of which
are well-established STAT target genes. These proteins
are rapidly transcribed and translated following Janus
kinase-signal transducer and activator of transcription
Abbreviations: ANOVA, analysis of variation; BET, bromodomain and extraterminal;
CALF, bovine calf serum; CISH, cytokine-inducible SH2-containing protein; cDNA,
complementary DNA; DMEM, Dulbecco’s Modified Eagle Media; DMSO, Dimethyl
sulfoxide; DNA, deoxyribonucleic acid; FBS, fetal bovine serum; GH, growth
hormone; GHR, GH receptor; HEXIM1, hexamethylene bis-acetamide inducible
1; HIV, human immunodeficiency virus; IP, immunoprecipitation; JAK, Janus kinase; KD, knockdown; m, mouse; mRNA, messenger RNA; NT, nontargeting; Pol II,
polymerase II; P-TEFb, positive transcription elongation factor; qPCR, quantitative
polymerase chain reaction; RNA, ribonucleic acid; RT, reverse transcription; SEC,
super elongation complex; SDS, sodium dodecyl sulfate; Ser2, serine 2; siRNA,
small interfering RNA; SOCS, suppressors of cytokine signaling; STAT, signal transducer and activator of transcription; TSS, transcription start site.
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JQ1 were opposite for 2 members of the SOCS family.
GH-mediated upregulation of Cish was decreased by
BET inhibition, while induction of Socs3 was substantially increased. Chromatin immunoprecipitation analysis demonstrated that changes in STAT5A binding to
the promoter region of these genes did not necessarily
correlate with changes in gene expression. We observed
that the BET protein BRD2 was recruited to the Cish
promoter by GH and that this recruitment was decreased by JQ1. Moreover, BRD2 knockdown (KD) decreased GH induction of Cish, further supporting the
dependency of Cish transcriptional activation on this
BET protein. In contrast, the upregulation of Socs3 by
JQ1 was attributed to enhanced mRNA elongation.
BET inhibitors have been reported to release P-TEFb
from its inhibitory complex and upregulate HEXIM1
(18). In our study, the BET inhibitor JQ1 transiently decreased the interaction between the regulatory subunit
of P-TEFb (Cyclin T1) and HEXIM1, rendering more
of the elongation factor available for recruitment to the
Socs3 promoter. Our data underscore the complexity of
the transcriptional effects of epigenetic modulators and
suggest that Socs3 and Cish may have different functions in adipocytes.

Experimental Procedures
Cell culture
Murine 3T3-L1 preadipocytes (originally obtained
from lab H, Green lab at Harvard Medical School)
were grown to 2 days after confluence in Dulbecco’s
Modified Eagle Media (DMEM; Sigma-Aldrich, St.
Louis, MO) with 10% bovine calf serum (CALF).
Cells were induced to differentiate using a standard
MDI induction cocktail of 0.5 mM 3-isobutyl-1methylxanthine (MIX), 1 μM dexamethasone, and
1.7 μM insulin in DMEM containing 10% characterized fetal bovine serum (FBS). Cell identity was confirmed for each group of cells by monitoring their
ability to differentiate into adipocytes, which contain
lipid droplets that can be observed via phase-contrast
microscopy. HyClone CALF and FBS were purchased
from Thermo Scientific or GE Healthcare Life Sciences
(Logan, UT). The medium was changed every 48 to
72 hours during all phases of growth and differentiation. When specified, cells were serum deprived
with DMEM containing 0.3% bovine serum albumin
(BSA; Cat #: A6003, Sigma-Aldrich, St. Louis, MO).
Otherwise, cells were serum deprived by changing the
media to DMEM containing 1% CALF for 16 to 24
hours before treatment with the inhibitor. (+)-JQ1
was purchased from Sigma-Aldrich (Millipore Sigma).
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(JAK-STAT) pathway activation, and they function to
turn off JAK-STAT signaling via a negative feedback
loop (2). In adipocytes, growth hormone (GH) or prolactin can activate STAT5 (3, 4), and a number of studies
have demonstrated that this transcription factor is important for adipocyte development and function (5).
The regulation of important physiological processes,
such as carbohydrate and lipid metabolism, by GH is,
at least in part, accomplished by its effects on gene transcription (6). For example, GH can upregulate insulin
growth factor 1 in the liver and other tissues, including
adipose tissue (7, 8). Conversely, GH-induced binding
of STAT5 to the promoter of B-cell lymphoma 6 (BCL6)
gene inhibits its expression (9).
Bromodomain and extraterminal (BET) proteins
(BRDT, BRD2, BRD3, and BRD4) are epigenetic readers
that bind to acetylated histones and promote transcription, forming a link between chromatin remodeling
and transcription factors. BETs can recruit the positive
transcription elongation factor b (P-TEFb), a cyclindependent kinase composed of 2 cyclin-dependent
kinase 9 catalytic subunits and 2 regulatory subunits,
which are usually cyclin T1 (10). P-TEFb phosphorylates the C-terminal domain of ribonucleic acid polymerase II (RNA polymerase II) on serine 2 (Ser2), an
essential modification for transcription elongation (11).
Inhibition of BET proteins by small molecules has been
extensively studied for treating cancer (12–14) and inflammatory states (15, 16). BET inhibition is generally
associated with reduced transcriptional activation and,
consequently, with decreased gene expression. Notably,
however, studies have shown that gene transcription of
human immunodeficiency virus (HIV)-1 is dependent
on P-TEFb (17) and can be increased by BET inhibition (18, 19). This upregulation is explained by a secondary effect of BET inhibitors to release P-TEFb from
its inhibitory complex so that it is more available for
transcript elongation (18, 20). In normal cellular conditions, where inducible genes contain Pol II poised at
their promoters, elongation is tightly regulated by the
equilibrium between inactive P-TEFb that is associated
with the scaffold 7SK noncoding RNA and HEXIM1
(hexamethylene bis-acetamide inducible 1) and a free active form of P-TEFb that can be recruited by other proteins including BRD4 and the super elongation complex
(SEC) (18). BET proteins have also been shown to be
involved in STAT5 transcriptional activity (14, 21) and
may, therefore, play a role in the regulation of STAT5
target genes in adipocytes.
The goal of our study was to examine how BET
inhibition would affect the ability of GH to regulate
STAT5 target genes using murine 3T3-L1 adipocytes
as a model system. The effects of the BET inhibitor
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primers purchased from Integrated DNA Technologies
(IDT, Skokie, IL). Primer sequences for each gene are
shown in Table 1.

Antibodies
Antibodies against BRD2 (22) (D89B4; rabbit monoclonal), lamin B1 (23) (D4Q4Z; rabbit monoclonal),
and rabbit IgG (24) (2729; rabbit polyclonal) were
purchased from Cell Signaling Technology (Danvers,
MA). Anti-RNA Pol II CTD repeat YSPTSPS (pS2)
(25) (ChIP grade ab5095; rabbit polyclonal), cyclin
T1 (26) (ab184703; rabbit monoclonal), HEXIM1
(27) (ab25388; rabbit polyclonal), STAT5A (28)
(E289; rabbit monoclonal; for WB Cat# ab32043; for
ChIP Cat#: ab213219) were purchased from Abcam
(Cambridge, MA). Anti-BRD4 (29) (PA5-41550;
rabbit polyclonal) was purchased from ThermoFisher
Scientific (Waltham, MA). Anti-histone H3 (30) (06599; rabbit polyclonal), histone H4 (31) (06-866;
rabbit polyclonal), RNA Pol II (32) (17-620; mouse
monoclonal) and control mouse IgG were purchased
from Millipore Sigma (Burlington, MA).

Chromatin immunoprecipitation
The medium on mature 3T3-L1 adipocytes (7–15 days
post-MDI) was replaced with 1% CALF for 16 to 24
hours. Following a 30-minute pretreatment with JQ1 or
dimethyl sulfoxide (DMSO) (control), cells were treated
with vehicle or GH for 30 minutes. DNA-protein
crosslinking, nuclear preparation, chromatin digestion,
and chromatin immunoprecipitation (ChIP) assays were
performed using the SimpleChIP kit (Magnetic Beads)
from Cell Signaling Technology (Cat #: 9003S; Danvers,
MA) according to the manufacturer’s instructions. For
each ChIP, 8 to 12 μg of digested, cross-linked chromatin were incubated with the following amounts of
antibodies, as recommended by their respective manufacturers: rabbit anti-STAT5A (28) (2 μg), mouse antiRNA Pol II (32) (1 μg), rabbit anti-phosphoserine2 RNA
Pol II (25) (4 μg), rabbit anti-BRD2 (22) 1:50 dilution,
rabbit BRD4 (29) (1 μg), rabbit ac-histone H3 (5 μL),
rabbit ac-histone H4 (5 μL), nonimmune IgG control
antibody rabbit IgG (24) from ChIP kit (2 μg) or mouse
IgG from RNA Pol II kit (1 μg). After protein digestion and DNA purification using the columns provided
in the SimpleChIP kit, input and immunoprecipitated
DNA samples were analyzed using real-time qPCR on
the Applied Biosystems 7900HT Fast Real-Time PCR
System. We used the qPCR amplification program specified in the kit instructions with the exception that the
initial denaturation step was performed for 10 minutes
at 95°C. We also added a dissociation curve step at the
end of the reaction. Primers used to amplify different
regions of the Cish and Socs3 genes are described in
Table 2. A standard curve prepared with only 2% input
samples and 5-fold serial dilutions was made to assess
amplification efficiency.
IP efficiency was calculated using the percent
input approach and the following equation: Percent

Reverse transcription–quantitative polymerase
chain reaction
Total RNA was purified from harvested 3T3-L1 adipocyte monolayers using the RNeasy mini kit from Qiagen
(Hilden, Germany). RNA levels were quantified by spectrophotometry. Complementary deoxyribonucleic acid
(cDNA) was synthesized by reverse transcription (RT)
with the High-Capacity cDNA Reverse Transcription kit
(Applied Biosystems, Foster City, CA), according to the
manufacturer’s protocol. Genes of interest were quantified by real-time quantitative PCR (qPCR) using Takara
SYBR Premix (Takara Bio USA, Mountain View, CA)
and the Applied Biosystems 7900HT Fast Real-Time
PCR System. Cyclophilin a and NoNo were used as reference genes. The following mouse (m) genes were examined by RT-qPCR: mCyclophilin a, mNoNo, mSocs3,
mCish, mBcl6, mIgf1, mSocs2, mBrd2, mHexim1 using
Table 1. Primers Used for RT-qPCR
Gene

Primer 1

Primer 2

Bcl6
Brd2
Cish
Cyclophilin a (Ppia)
Hexim1
Igf1
Nono
Socs2
Socs3

5’-AGTCACATTCGTTGCAGAAGA-3’
5’-GGTTCCCTGAGGTCAAGATG-3’
5’-CCGCCCAATTTGCTCCA-3’
5’-TCTTCAGGTCAATAGTCAAGCC-3’
5’-CAGCCTCAAACTAGCAACTGTA-3’
5’-ATGCTCTTCAGTTCGTGTGT-3’
5’-CATCATCAGCATCACCACCA-3’
5’-TCTGGGGACTGCCTTTACCAAC-3’
5’-GGAAACTTGCTGTGGGTGA-3’

5’-CAGAGATGTGCCTCCATACTG-3’
5’-TCGAATCCTTTTCCCTGGTG-3’
5’-GCTCCTTTCTCCTTCCATCC-3’
5’-TGCAAACAGCTCGAAGGAGACGC-3’
5’-CTCGATTGCCACCTACTGTC-3’
5’-AGTACATCTCCAGTCTCCTCAG-3’
5’-TCTTCAGGTCAATAGTCAAGCC-3’
5’-CCTCTGGGTTCTCTTTCACATAGC-3’
5’-GAGATTTCGCTTCGGGACTA-3’

Abbreviation: RT-qPCR, reverse transcription–polymerase chain reaction.
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Recombinant murine GH was purchased from Dr A.F.
Parlow at the National Hormone and Peptide Program
(NHPP; Torrance, CA).
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Table 2. Primers Used for ChIP-qPCR
Forward

Reverse

Cish SBS
Cish TSS
Cish Coding
Socs3 SBS
Socs3 TSS
Socs3 Coding

5’-CGTCCAGCGATACGATTGGT-3’
5’-GTTCGCACCACAGCCTTTCAGTCC-3’
5’-TACCCCTTCCAACTCTGACTGAGC-3’
5’-GCACAGCCTTTCAGTGCAGAG-3’
5’-GCGTACTGGCCGGGTAAATAC-3’
5’-CATTTAGAAGGGAGACAGATGAG-3’

5’-CAGGCGTCTAGTGCTTTGGA-3’
5’-TGCCAGGGGTGCGAAGGTCAGG-3’
5’-TTCCCTCCAGGATGTGACTGTG-3’
5’-GTATTTACCCGGCCAGTACGC-3’
5’-GGAGAGACAGCGGTCGTAAG-3’
5’-CATAGGAGAGACAAAGCAGAAC-3’

Abbreviation: ChIP, chromatin immunoprecipitation; qPCR, quantitative polymerase chain reaction; SBS, STAT binding site; TSS, transcription start site.

Figure 1. Regulation of STAT5 target genes by GH. Mature 3T3-L1 adipocytes were treated with 5 nM GH in triplicate and harvested at indicated
time points. Relative gene expression of Socs3, Cish, Igf1, Socs2, and Bcl6 were quantified by RT-qPCR using cyclophilin a as the housekeeping
gene. This experiment was replicated at least 3 times in different batches of cells. Data are presented as means ± SE (n = 3 per treatment). All
time points are compared to time 0. Statistical significance was determined using one-way ANOVA. *P < 0.05, **P < 0.005, ***P < 0.001,
****P < 0.0001. Abbreviations: ANOVA, analysis of variance; GH, growth hormone; RT-qPCR, reverse transcription–quantitative polymerase chain
reaction; SE, standard error; STAT, signal transducer and activator of transcription.

input = 2% × 2(C[T] 2% Input Sample– C[T] Input Sample); where
C[T] = threshold cycle of the PCR reaction. Percent input
of control rabbit and mouse IgG was calculated for all

the regions analyzed and ranged from 0.03% to 0.1%.
The coding regions of Socs3 and Cish were used as control regions lacking STAT binding sites. STAT5-specific

Downloaded from https://academic.oup.com/endo/article/161/2/bqz034/5686880 by Louisiana State University user on 10 August 2021

Gene Region

doi: 10.1210/endocr/bqz034

Preparation of whole-cell extracts
Cell monolayers were rinsed once with phosphate buffered saline and then scraped into nondenaturing IP buffer
that contained 10 mM Tris (pH 7.4), 150 mM NaCl,
1 mM ethylene glycol-bis(β-aminoethyl ether)-N,N,N’,N’tetraacetic acid (EGTA), 1 mM ethylenediaminetetraacetic
acid (EDTA), 1% Triton X-100, 0.5% IGEPAL CA-630,
protease inhibitors (1 mM phenylmethylsulfonyl
fluoride [PMSF], 1 μM pepstatin, 50 trypsin inhibitory milliunits of aprotinin, 10 μM leupeptin, 1mM 1,
10-phenanthroline), and phosphatase inhibitors (100 μM
sodium fluoride and 0.2 mM sodium vanadate). The cell
suspension was subjected to a freeze/thaw cycle at –80°C
and then passed through a 20-gauge needle 5 times.
The whole-cell extract was clarified by centrifugation at
13 000 × g for 10 minutes at 4°C.
Measurement of protein concentration
Protein content of cell and tissue extracts was determined using the bicinchoninic acid assay kit from
Sigma-Aldrich (Cat #: BCA1).
Gel electrophoresis and immunoblotting
Samples were separated on 6% or 7.5% sodium
dodecyl sulfate (SDS) polyacrylamide gels (acrylamide,
Cat #: EC-890, from National Diagnostics, Atlanta,
GA) and transferred to nitrocellulose membranes (Cat
#: 162-0115, BioRad, Hercules, CA). Results were visualized with horseradish peroxidase-conjugated secondary antibodies (Jackson ImmunoResearch, West
Grove, PA) and enhanced chemiluminescence (Pierce/
Thermo Scientific, Rockford, IL).
Small interfering RNA-mediated knockdown
3T3-L1 mature adipocytes (5–7 days post-MDI) were
trypsinized from 6-well plates and re-plated in 12-well
plates at a density of 1.16 × 105 cells/cm2 in antibioticfree medium (10% FBS/DMEM). Adipocytes were transfected using DharmaFECT Duo reagent (Dharmacon;
Cat #: T-2010-03) and 50 nM of nontargeting (NT;
Cat #: D-001810-10-50) or Brd2 (Cat #: L-04340400-0005) small interfering RNA (siRNA) in OptiMEM
reduced serum medium (Thermo Fisher; Cat #:
31985088). Twenty-four hours later, siRNA-containing
media was removed and replaced with antibiotic-free

10% FBS/DMEM. After 24 hours, adipocytes were
transfected again with NT or Brd2 siRNA. siRNAcontaining medium was removed 24 hours later and replaced with 10% FBS. After 24 hours, FBS was replaced
by 1% CALF, antibiotic-free. The next day, cells were
treated with vehicle or 5 nM GH for 1 hour. Adipocytes
were harvested in RLT buffer (Qiagen) for RNA analysis, and whole-cell extracts were collected in IP buffer
for protein quantification.
Immunoprecipitation
Cell extracts (300 μg total protein) were incubated
with 5 μl of anti-cyclin T1 antibody overnight on a
mini-tube rotator at 4°C. Protein A-conjugated agarose
(IPA300 Protein A Resin; Cat #: 10-2003-02) from
Repligen (Waltham, MA) or Protein A/G Plus-agarose
(Cat #: sc-2003) beads from Santa Cruz Biotechnology
(Dallas, TX) were added to the antibody-epitope mixture. The conjugation reaction continued for an additional 1 to 2 hours at 4°C with rotation. Next, the
beads were pelleted by centrifugation at 13 000 rpm
for 3 minutes at 4°C. The supernatant was removed
by aspiration, and the beads were washed 3 times with
ice-cold 1X IP buffer containing protease inhibitors.
Between each wash, the beads were pelleted by centrifugation at 12 000 rpm for 1 minute at 4°C and the
supernatant removed by aspiration. After the final wash,
the IP antibody and immunoprecipitated proteins were
eluted from the bead resin into 2X SDS loading buffer
by boiling the samples for 10 minutes at 100°C. Samples
were flicked multiple times during the heat step to ensure efficient elution. The samples were briefly centrifuged and the supernatants analyzed by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
and immunoblotting. A mock sample containing a pool
of equal concentration of all samples and no IP antibody
was used as a negative control to ensure that there was
no unspecific binding of the beads to protein samples.
Statistical analysis
Data were plotted as mean ± standard error (SE). The
qPCR data were analyzed using either using one-way
analysis of variation (ANOVA) or two-way ANOVA. For
ChIP experiments, data were analyzed using two-way
ANOVA with the Bonferroni post hoc test. Differences
with P < 0.05 were considered statistically significant.

Results
GH regulation of STAT5 target genes in
adipocytes
In order to study the modulation of STAT5 target
genes in 3T3-L1 adipocytes, cells were treated with GH
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binding was at least 50-fold higher at Cish promoter
and 30-fold higher at Socs3 promoter when compared
with the nonspecific coding region or for nonimmune
IgG binding at the same sites. BRD2 binding to Cish
promoter was 10-fold higher than binding to the coding
region, while BRD2 binding to Socs3 promoter was
only 2-fold higher than binding to the coding region.
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BET inhibition increased GH-induced Socs3
expression and decreased GH-induced Cish
expression
The thienotriazolodiazepine JQ1 competitively binds
to bromodomains of BET proteins and prevents their
binding to chromatin. Only (+)-JQ1 interacts with
bromodomains; the enantiomer (−)-JQ1 does not inhibit
BET proteins (38). As shown in Fig. 2A, BET inhibition

using the active enantiomer (+)-JQ1 decreased GH induction of Cish and increased Socs3 upregulation in a
dose-dependent manner. In addition, the effects of JQ1
on GH induction of Cish and Socs3 were acute, as only
30 minutes of pretreatment were sufficient to produce
these opposite effects on Cish and Socs3 expression
(Fig. 2B). The effects of BET inhibition decreased over
time, probably because of JQ1’s short half-life (39). In
vehicle conditions, there were no statistically significant
differences between treatments.
GH recruits BRD2 to the Cish promoter, and JQ1
decreases BRD2 and RNA Pol ll recruitment
Since GH treatment induces the JAK-STAT signaling
pathway and STATs modulate transcription of target
genes, we investigated the effects of JQ1 on binding of
various transcriptional regulators to distinct sites in the
promoters or coding sequences of the Socs3 or Cish
genes. Fig. 3A illustrates the 3 target regions of Cish
that were amplified by qPCR: one region containing
STAT binding sites (SBS), another containing the transcription start site (TSS), and a third within the coding
region of Cish. Results demonstrated that GH and JQ1
each modestly increased STAT5A binding to the Cish

Figure 2. JQ1 upregulates Socs3 and downregulates Cish. (A) Mature 3T3-L1 adipocytes were pretreated for 30 minutes with JQ1 at different
concentrations. Vehicle or 5 nM of GH were added 1 hour before the cells were harvested. (B) Mature adipocytes were pretreated with 1 μM JQ1
for indicated times, and vehicle or 5 nM of GH were added 1 hour before the cells were harvested. Gene expression levels were quantified by
RT-qPCR. Cyclophilin a was used as the reference gene. Data are presented as means ± SE (n = 3 per treatment). This experiment was replicated
3 times in different batches of cells. Treatments were normalized to vehicle condition in the absence of inhibitor. Statistical significance was
determined using two-way ANOVA. *P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001. Abbreviations: ANOVA, analysis of variance; GH,
growth hormone; RT-qPCR, reverse transcription–quantitative polymerase chain reaction; SE, standard error.
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and harvested at different time points, up to 48 hours.
The expression of STAT5 target genes was analyzed
by RT-qPCR (Fig. 1). As expected, Socs3 and Cish
were acutely regulated by GH treatment. The induction of Socs3 mRNA was evident at 30 minutes, and
the maximal response was observed at one hour. Cish
was upregulated at one hour and remained elevated
after 48 hours. Bcl6 expression was downregulated by
GH at early time points and remained low over the
course of treatment. Socs2 and Igf1 were also induced
by GH, but at later time points. Since Socs3 and Cish
are well characterized in other model systems (33–37)
and were acutely induced by GH at early time points,
we focused our additional studies on these 2 STAT5
target genes.

Endocrinology, XXXX 2020, 161(2):1–15
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Figure 3. Recruitment of RNA Pol II to Cish TSS highly correlates to BRD2 recruitment. (A) Schematics of Cish regions that were amplified by qPCR
in ChIP assay, including STAT binding site, transcription start site (TSS) and coding region of the gene. (B-F). Mature adipocytes were pretreated
with 2 μM JQ1 or DMSO for 30 minutes. Next, cells were treated with vehicle (V; NaHCO3) or 5 nM GH for 35 minutes. Chromatin was cross-linked
using formaldehyde, and nuclear extracts were subjected to ChIP using specific antibodies. The amount of bound DNA was measured by qPCR and
percentage input was calculated. IP efficiency (% input) of (B) STAT5A binding to STAT binding site, (C) BRD2, (D) BRD4, (E) total RNA polymerase
II, (G) ac-histone H3, (H) ac-histone H4 binding to Cish TSS and (F) RNA Pol IIpS2 binding to Cish coding region. This experiment was replicated
3 times in different batches of cells. Statistical significance was calculated using two-way ANOVA and the Bonferroni post hoc test. * denotes
significance among V and GH in the presence or absence of JQ1. # denotes significance between DMSO and JQ1 in the presence or absence
of GH. *P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001; #P < 0.05, ###P < 0.005, ###P < 0.001, ####P < 0.0001. Abbreviations: ANOVA,
analysis of variance; ChIP, chromatin immunoprecipitation; DMSO, dimethyl sulfoxide; GH, growth hormone; Pol II, polymerase II, RNA, ribonucleic
acid; RT-qPCR, reverse transcription–quantitative polymerase chain reaction; STAT, signal transducer and activator of transcription; TSS, transcription
start site.
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JQ1 increases Socs3 mRNA elongation
Fig. 4A illustrates the 3 target regions of Socs3 that
were amplified by qPCR. STAT5A interaction with its
binding site in Socs3 was strongly enhanced by GH but
minimally affected by JQ1 treatment, indicating that the
effect of JQ1 on GH-induced Socs3 expression was not
the result of increased STAT5A binding (Fig. 4B). In contrast to what we observed at the Cish TSS, BRD2 was
not recruited to the Socs3 TSS by GH, and JQ1 modestly decreased its binding (Fig. 4C). BRD4 binding to
the Socs3 TSS was somewhat higher than binding to the
Cish TSS, but it was not substantially affected by GH or
JQ1 (Fig. 4D). RNA Pol II recruitment to the Socs3 TSS
was increased by GH; JQ1 enhanced Pol II recruitment
in the vehicle condition but had no effect in GH conditions (Fig. 4E). Therefore, changes in BRD2 or RNA Pol
II recruitment to the Socs3 promoter did not explain the
greater upregulation of Socs3 expression by JQ1 either.
Binding of activated Pol II to the Socs3 coding region,
however, was robustly increased by JQ1, suggesting that
the upregulation of Socs3 gene expression by JQ1 is due
to augmented mRNA elongation (Fig. 4F). Acetylated
histone H3 (Fig. 4G) and H4 (Fig. 4H) levels were much
lower at Socs3 TSS when compared to Cish. In addition, neither GH nor JQ1 had any notable influence on

acetylated histone H3 levels. GH increased ac-histone
H4 only in the presence of JQ1.
BRD2 knockdown decreases GH activation
of Cish
Our ChIP experiments demonstrated that BRD2
was recruited to the Cish promoter by GH, and JQ1
decreased this recruitment. To determine whether the
effects of JQ1 were dependent on BRD2, we used an
siRNA KD approach. Fig. 5A shows mRNA levels of
Brd2, Socs3, and Cish. KD efficiency at the mRNA
level was about 50%. In basal conditions, neither
Cish nor Socs3 expression was affected by Brd2 KD.
However, only GH activation of Cish was reduced by
Brd2 KD, further supporting the hypothesis that BRD2
is necessary for GH activation of Cish. In contrast, the
upregulation of Socs3 by JQ1 was not recapitulated by
BRD2 KD, ruling out the possibility that BRD2 was
acting as a negative regulator of Socs3. BRD2 protein
levels were decreased by about 80% in the KD conditions versus the NT control, and GH had no effect on
BRD2 protein expression (Fig. 5B).
JQ1 interferes with P-TEFb availability and
upregulates HEXIM1
To explain why JQ1 upregulates Socs3, we scoured
the literature for examples of genes upregulated by BET
inhibition. Curiously, JQ1 was reported to upregulate
HIV-1 expression through the transient release of
P-TEFb from its inhibitory complex, leading to compensatory upregulation of HEXIM1 (18). To investigate
if this could occur for GH-induced Socs3 transcription,
we treated 3T3-L1 adipocytes with DMSO or JQ1 for
2, 6, or 24 hours and examined Hexim1, Socs3, and
Cish gene expression. Interestingly, JQ1 substantially
upregulated Hexim1; levels peaked at 6 hours and
started to decrease at 24 hours but remained significantly higher than in the DMSO control. Adipocytes
were also treated with GH for 1 hour before harvesting
for induction of Socs3 and Cish and for confirmation
of inhibitor effects (Fig. 6A). In addition, we measured
HEXIM1 protein levels at the same time points and observed a progressive accumulation of HEXIM1 when
the cells were treated with JQ1. We also found that JQ1
upregulated BRD2 protein levels. Quantification and
fold change of BRD2 and HEXIM1 using cyclin T1 as a
control is shown below the Western blot images (Fig. 6B).
Lastly, cell lysates were immunoprecipitated with cyclin
T1 antibody (the regulatory portion of P-TEFb) to
evaluate the impacts of JQ1 on P-TEFb availability. In
Fig. 6C, quantification values of BRD2 and HEXIM1
were divided by cyclin T1, and graphs are shown below
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STAT binding site (Fig. 3B), but that JQ1 had no further
effect on STAT5A binding in the presence of GH. As
BRD4 is the most well-studied BET protein and BRD2
was previously described to be involved in STAT5 transcriptional regulation (14, 21), binding of BRD2 and
BRD4 to the Cish TSS was also investigated. BRD2 was
recruited to Cish TSS by GH, and its binding was suppressed by JQ1 (Fig. 3C). BRD4 binding levels were
low, ranging from 0.06% to 0.2% input, only slightly
higher than IgG levels ranging from 0.03% to 0.1%
input (data not shown). In addition, BRD4 binding
was not substantially altered by GH or JQ1 treatment
(Fig. 3D). As expected, total RNA Pol II binding to Cish
TSS was increased by GH treatment. In the presence of
JQ1, this RNA Pol II recruitment to Cish TSS was decreased (Fig. 3E). Similarly, the binding of Pol II phosphorylated at Ser2, a marker of RNA elongation, to
the coding region of Cish was increased with GH and
suppressed by JQ1 (Fig. 3F). Since BET proteins bind to
acetylated histones, we also assessed the levels of total
acetylated histone H3 (Fig. 3G) and H4 (Fig. 3H) at the
Cish TSS. In the presence or absence of JQ1, GH highly
increased ac-histone H3 and H4 at the Cish promoter.
JQ1 further increased only ac-histone H4 in the presence of GH.
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Figure 4. Socs3 mRNA elongation is enhanced by JQ1. (A) Schematics of Socs3 regions that were amplified by qPCR in ChIP assay, including
STAT binding site, transcription start site (TSS), and coding region of the gene. (B-F). Mature adipocytes were pretreated with 2 μM JQ1 or DMSO
for 30 minutes. Next, cells were treated with vehicle (V; NaHCO3) or 5 nM GH for 35 minutes. Chromatin was cross-linked using formaldehyde,
and nuclear extracts were subjected to ChIP using specific antibodies. The amount of bound DNA was measured by qPCR and percentage input
was calculated. IP efficiency (% input) of (B) STAT5A binding to STAT binding site, (C) BRD2, (D) BRD4, (E) total RNA polymerase II (Pol II), (G)
ac-histone H3, (H) ac-histone H4 binding to Cish TSS, and (F) RNA Pol IIpS2 binding to Cish coding region. This experiment was replicated 3
times in different batches of cells. Statistical significance was calculated using two-way ANOVA and the Bonferroni post hoc test. * denotes
significance among V and GH in the presence or absence of JQ1. # denotes significance between DMSO and JQ1 in the presence or absence of
GH. *P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001; #P < 0.05, ###P < 0.005, ###P < 0.001, ####P < 0.0001. Abbreviations: ChIP, chromatin
immunoprecipitation; DMSO, dimethyl sulfoxide; DNA, deoxyribonucleic acid; mRNA, messenger ribonucleic acid; qPCR, quantitative polymerase
chain reaction; STAT, signal transducer and activator of transcription.
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Figure 5. BRD2 knockdown (KD) downregulates growth hormone (GH)-induction of Cish and has no effect on Socs3 expression. Fully
differentiated 3T3-L1 adipocytes were transfected with 50 nM nontargeting (NT) siRNA or Brd2 siRNA. siRNA-containing media was removed
24 hours later and replaced with 10% FBS. After 48 hours, adipocytes were transfected again with NT or Brd2 siRNA. siRNA-containing
media was removed 24 hours later and replaced with 10% FBS. After 24 hours, FBS was replaced by 1% CALF. The next day, cells were
treated with vehicle (NaHCO3) or 5 nM murine growth hormone (GH) for 1 hour. (A) Cells were collected in RLT lysis buffer (Qiagen). Total
RNA was isolated and subjected to RT-qPCR analysis. Brd2, Socs3 and Cish mRNA levels were measured. Nono was used as the reference
gene. (B) Whole-cell extracts were collected in IP buffer, and 30 μg of protein was used for gel electrophoresis. BRD2 and lamin B1 protein levels
were detected by Western blot. Band intensities were quantified and fold change was calculated by dividing BRD2/lamin B2 and is represented
below Western blot images. Data are presented as means ± SE (n = 3 per treatment). This experiment was replicated 2 times in different batches of
cells. Statistical significance was determined using two-way ANOVA. *P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001 for comparisons
of NT versus Brd2 KD. Abbreviations: ANOVA, analysis of variance; CALF, bovine calf serum; FBS, fetal bovine serum; IP, immunoprecipitation;
mRNA, messenger ribonucleic acid; RT-qPCR, reverse transcription–quantitative polymerase chain reaction; SE, standard error; siRNA, small
interfering RNA.
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the Western blot images. For the 2-hour JQ1 treatment,
the interaction between cyclin T1 and HEXIM1 was
reduced, while interaction with BRD2 was increased.
As the interaction with HEXIM1 increased over time,
the interaction with BRD2 decreased. The highest increase in Socs3 expression occurs at 2 hours for JQ1
treatment, when the interaction between HEXIM1 and
cyclin T1 is maximally inhibited. As HEXIM1 protein
levels increase and P-TEFb complex is reassembled, the
JQ1-induced increase in GH-activated Socs3 expression
decreases. These results confirmed that JQ1 has an offtarget effect on P-TEFb availability in adipocytes.

Discussion
The transcription factor STAT5 has been extensively
studied for its pathophysiological roles in cancer because
its constitutive activation can lead to dysregulation of cell
development and survival (40–43); it is also known to
play an important role in fat cell development and function (5, 44, 45). However, the exact molecular mechanisms by which STAT5 impacts cell fate and physiology
are still poorly understood. The BET protein, BRD2, has
been reported to be involved in STAT5-mediated transcription (14, 21). In our investigation, treatment of adipocytes with the BET inhibitor JQ1 produced divergent
effects on 2 well-known STAT5 target genes. GH activation of Cish was reduced, while activation of Socs3 was
even greater in the presence of JQ1 (Fig. 2).
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Figure 6. JQ1 transiently upregulates Hexim1 expression and decreases its interaction with cyclin T1. (A) Mature adipocytes were treated with
DMSO or 2 μM JQ1 for 2, 6, or 24 hours. Cish, Socs3, and Hexim1 gene expression levels were quantified by RT-qPCR. Nono was used as the
reference gene. Samples were normalized to controls treated with DMSO (JQ1 vehicle) and NaHCO3 (GH vehicle). Data from GH-treated samples
are shown and presented as means ± SE (n = 3 per treatment). Statistical significance was calculated using two-way ANOVA with the Bonferroni
post hoc test. * denotes significance among DMSO and JQ1 treatment. # denotes significance between 2 hours and the other time points.
*P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001; #P < 0.05, ###P < 0.005, ###P < 0.001, ####P < 0.0001. (B) 3T3-L1 mature adipocytes
were treated with 2 μM JQ1 for the indicated time points. Control (CTL) cells were untreated. Whole-cell extracts were collected in IP buffer, and
25 μg of protein was used for gel electrophoresis. HEXIM1, BRD2, and cyclin T1 protein levels were detected by Western blot. (C) From the same
experiment as B, 300 μg of total protein was incubated with anti-cyclin T1 antibody overnight. Interacting HEXIM1 and BRD2 were detected
by Western blot. The mock sample was composed of a pool of all samples without any antibody. For B and C, band intensities were quantified
and cyclin T1 was used as a loading control to calculate fold change. Quantification graphs are shown below immunoblot images. Statistical
significance was calculated using one-way ANOVA. * denotes significance between CTL and other treatments as described for A. Abbreviations:
ANOVA, analysis of variance; DMSO, dimethyl sulfoxide; GH, growth hormone; RT-qPCR, reverse transcription–quantitative polymerase chain
reaction; SE, standard error.
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but may instead constitute an off-target effect whereby
JQ1 (18) and other BET inhibitors (47) induce the release of P-TEFb from its inhibitory complex. HEXIM1
acts to inhibit P-TEFb when they are both associated
with 7SK small nuclear RNA (48). In our experiments,
the decreased association between cyclin T1 (the regulatory subunit of P-TEFb) and HEXIM1 following
JQ1 exposure coupled with the increased association
between BRD2 and cyclin T1 (Fig. 6C), as well as the
upregulation of HEXIM1 (Fig. 6B), support the hypothesis that JQ1 interferes with the binding of P-TEFb to its
inhibitory complex. Disruption of the P-TEFb inhibitory
complex increases P-TEFb availability and also activates
cellular feedback mechanisms to upregulate HEXIM1
expression and reassemble the 7SK small nuclear RNA
inhibitory complex (18, 49). Nonetheless, our findings
do not exclude the possibility that the upregulation of
Socs3 by JQ1 is not a direct effect on HEXIM1–P-TEFb
interaction, and other modulators of mRNA elongation
might be affected by BET inhibition.
Most studies have focused on BRD4 interaction with
the P-TEFb complex via its cyclin T1 subunit. Our study
confirms that BRD2 can also be present in a complex
with cyclin T1. Further investigation will be required to
determine whether this interaction is direct or mediated
by other proteins. Among all BETs, only BRD4 possesses
a C-terminal segment called P-TEFb interacting domain
that can actively dissociate P-TEFb from HEXIM1. But
depletion of that domain does not completely eliminate
the association between BRD4 and cyclinT1 (50, 51),
indicating that another region of BET proteins may facilitate this interaction.
Our results support the model shown in Fig. 7 where
the upregulation of Socs3 by JQ1 is due to interference with the P-TEFb inhibitory complex. While more
studies will be needed to fully explain the divergent
transcriptional regulation of Socs3 and Cish, our hypothetical model suggests that GH upregulation of Cish is
dependent on BRD2 recruitment to the promoter and
on recruitment of RNA Pol II and P-TEFb for transcript
elongation. When JQ1 is present, it displaces BRD2
from the Cish promoter, thus decreasing its gene expression. GH upregulation of Socs3, on the other hand, is
likely dependent on another factor. Since P-TEFb, when
not bound to its inhibitory complex, is reported to associate with either BRD4 or the SEC (19, 52, 53), we hypothesize that SEC is responsible for recruiting P-TEFb
to the Socs3 promoter. When JQ1 is present, it disrupts
the interaction between P-TEFb and HEXIM1, allowing
more P-TEFb to be available for recruitment by SEC,
which could further increase GH-induced Socs3 expression (Fig. 7).
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ChIP was used to investigate the interaction of BET
proteins, STAT5, and RNA Pol II with the Socs3 and
Cish promoters, as well as the enrichment of RNA Pol
II phosphorylated at Ser2 on Socs3 and Cish coding regions. Changes in STAT5 binding were similar for both
genes, indicating that this was not driving the divergent
gene expression patterns (Figs 3B and 4B). Binding of
both BRD2 and RNA Pol II to the Cish TSS was increased by GH and suppressed by the BET inhibitor JQ1
(Fig. 3C and E). We therefore hypothesized that BRD2,
which is required for GH-induced Cish transcription,
was displaced from the TSS by JQ1, thus affecting RNA
Pol II recruitment and consequently decreasing the
ability of GH to induce Cish gene expression. Since BET
proteins bind to acetylated histones, we also assessed
histone H3 and H4 acetylation at the Socs3 and Cish
promoters and observed higher total acetylation levels
at the Cish (Fig. 3G and H) promoter compared with
Socs3 (Fig. 4G and H). In addition, at basal conditions,
GH increased acetylation at the Cish, but not the Socs3,
TSS (transcription start site). These results support the
hypothesis that GH induction of Cish gene expression is
dependent on increased acetylation at the promoter to
facilitate the recruitment of BRD2 to acetylated lysines
at the Cish TSS. In the presence of JQ1, BRD2 binding
is decreased and may consequently affect recruitment
of the basal transcription machinery. This phenomenon
has been similarly described for interleukin-3 activation
of Cish in Ba/F3 cells (21). BRD2 involvement in GH activation of Cish was further confirmed by the observed
reduction in Cish expression when BRD2 was knocked
down using siRNA (Fig. 5A).
BRD2 was not recruited to the Socs3 promoter by
GH, and BET inhibition had only minor effects on
BRD2 binding to the Socs3 TSS (Fig. 4C), suggesting
that BRD2 is not required for GH-regulated Socs3
expression. RNA Pol II recruitment to Socs3 was enhanced by JQ1 in basal conditions, but not in the
presence of GH (Fig. 4E). On the other hand, enrichment of phosphorylated Pol II to the coding region of
Socs3 was highly augmented by JQ1 (Fig. 4F). Since
RNA Pol II phosphorylated at Ser2 is a well-known
marker of elongation, we concluded that JQ1 increases
Socs3 mRNA elongation. Although we did not directly
measure the binding of the elongation factor P-TEFb to
Cish or Socs3 promoters, we know that RNA Pol II is
primarily phosphorylated at Ser2 by P-TEFb in metazoans (46).
The upregulation of Socs3 by JQ1 was at first challenging to explain; however, extensive work done in
the HIV field has shed light on how the inhibition of
BET proteins could upregulate some genes. In fact, the
phenomenon does not necessarily involve BET proteins
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SOCS3 and CISH are members of the suppressors
of the cytokine signaling family. All members of this
family possess a conserved Src homology 2 domain and
a C-terminal SOCS box. The Src homology 2 domain
inhibits the signaling pathway via direct or competitive binding to phosphorylated intermediates, while the
SOCS box can associate with ubiquitination machinery
that targets proteins to the proteasome for degradation
(54). Studies comparing SOCS proteins have revealed
different mechanisms of inhibition among the family
members. SOCS3 and SOCS1 possess a kinase inhibitory region (55) that is responsible for Janus kinase
(JAK) inhibition. SOCS3 can also bind simultaneously
to JAK and cytokine receptors, revealing higher levels
of specificity (56, 57). On the other hand, CISH does
not interact with JAKs. The binding of CISH to more
distal tyrosine residues of the growth hormone receptor
(GHR) leads to direct competition with STAT5 binding
sites. Alternatively, CISH is involved in a proteasomedependent mechanism that may induce GHR internalization and destruction of GHR–JAK2–CISH complexes
(6, 58).
Differences in the activation patterns of Socs3 and
Cish have been described (34, 37), and we have confirmed these differences in our studies. The fast and acute

upregulation of Socs3, with activation peaking between
30 minutes and 1 hour and a return to basal levels in 2
hours, represents a classical feedback loop. Cish, however,
is upregulated a little later and remains highly elevated
even after 48 hours of GH stimulation. Therefore, despite
similar protein structures and roles in inhibiting cytokine
signaling pathways, differences in gene activation patterns and divergent responses to BET inhibition demonstrate that Socs3 and Cish may have different functions,
at least in the context of cultured murine adipocytes.
The role of BET proteins in epigenetics and gene regulation has been an intensive area of research. Preclinical
studies have shown that the BET inhibitor OTX015 affects JAK/STAT signaling and can increase Hexim1 expression (59), suggesting an off-target effect on P-TEFb
regulation. Moreover, OTX015, is now in a phase 1b
clinical trial in patients with selected advanced solid
tumors (60). The results of our study also suggest an
off-target effect of JQ1 on P-TEFb regulation that influences STAT5 target gene expression in adipocytes. The
possibility that BET inhibitors affect the availability of
P-TEFb, the primary regulator of mRNA elongation, has
potentially broad biological consequences and should
be taken into consideration when these drugs are considered for therapeutic use. Furthermore, the fact that 2
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Figure 7. Model for potential differences between Socs3 and Cish gene expression. Under normal conditions, when 3T3-L1 adipocytes are
stimulated with GH, the JAK-STAT signaling pathway is activated. STAT5 dimerizes and binds to STAT binding sites within the Cish and Socs3
promoters. For the Cish promoter, BRD2 is recruited by GH treatment. Then, BRD2 binds acetylated histones and recruits the positive elongation
factor (P-TEFb), which is composed of 2 CDK9 and 2 cyclin T1 subunits. P-TEFb is responsible for the phosphorylation of Ser2 on the RNA Pol II
C-terminal domain (CTD) to promote elongation. When the cells are pretreated with JQ1 before GH stimulation, BRD2 is displaced from chromatin.
Therefore, P-TEFb is not recruited to Cish promoter. At the Socs3 promoter, GH treatment stimulates the recruitment of P-TEFb by another
factor, possibly the super elongation complex (SEC). P-TEFb then phosphorylates RNA Pol II and productive elongation occurs. When the cells are
pretreated with JQ1, in addition to release of BRD2 from chromatin, it also releases P-TEFb from its inhibitory complex. P-TEFb then becomes more
available to promote Socs3 elongation. Abbreviations: GH, growth hormone; JAK, Janus Kinase; RNA Pol II, ribonucleic acid polymerase II; Ser2,
serine 2; STAT, signal transducer and activator of transcription.
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very similar genes, Cish and Socs3, utilize different transcriptional machinery, resulting in such opposite regulation in the presence of JQ1, demonstrates how unique
and complex the regulation of GH-induced gene expression is and may have important implications in the feedback regulation of JAK/STAT signaling in adipocytes.
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